CHICAGO - More breast cancer detection, fewer false positives with digital tomosynthesis.
CHICAGO - Screening women with digital breast tomosynthesis (DBT) reduces callback rates and increases cancer detection rates, according to a study presented this week at RSNA 2013.
False positives from digital mammography result in a high recall level for additional imaging or biopsy. Researchers from the University of Pennsylvania in Philadelphia sought to determine if DBT, which allows for 3-D reconstruction of breast tissue, would reduce these false positives and increase cancer detection.
Although DBT is typically used as a supplemental screening tool in many facilities, all patients screened for breast cancer at the Hospital of the University of Pennsylvania since October 2011 have undergone DBT.
"Every patient has had [DBT],” lead author Emily F. Conant, MD, said in a release. “We have not selected patients because of their risk or breast density or if they were willing to pay extra."
A total of 15,633 DBT images were compared to 10,753 digital mammographies by six radiologists trained in DBT interpretation. They found that, compared to digital mammography, the average recall rate using DBT decreased 10.40 percent to 8.78 percent, and the cancer detection rate increased from 3.51 to 5.24 (per 1,000 patients). The overall positive predictive value - the proportion of positive screening mammograms from which cancer was diagnosed - increased from 4.1 percent to 6.0 percent with DBT.
Recall rates did vary by radiologist, but according to Conant, “the ratio of callback to cancer decision rate improved significantly for our radiologists.”
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.